<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070862</url>
  </required_header>
  <id_info>
    <org_study_id>020879</org_study_id>
    <nct_id>NCT01070862</nct_id>
  </id_info>
  <brief_title>Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.</brief_title>
  <acronym>MAG 2002</acronym>
  <official_title>Multiple Myeloma Treatment With Thalidomide. Three Randomized Studies on Thalidomide as Induction Treatment Before Autotransplant (MY-TAG) or With a Conventional Chemotherapy (MY-DECT) and as Consolidation/Maintenance at Plateau Phase (MY-PLAT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laphal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate efficacy and tolerability of Thalidomide in first-line
      treatment of multiple myeloma as induction treatment in young patients, with Dexamethasone
      before autotransplant, and in elderly patients in combination with conventional chemotherapy
      and as consolidation/maintenance therapy in young and elderly patients at plateau-phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MY-TAG : Thalidomide as induction treatment before high dose therapy, in young patients
      MY-DECT : Thalidomide as induction treatment with conventional chemotherapy, in elderly
      patients MY-PLAT : Thalidomide and Dexamethasone at plateau-phase, after high dose therapy or
      conventional chemotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>very good partial response rate (monclonal protein decrease of 90 % or more)at the end induction phase (MY-TAG and MY-DECT), progression free survival during consolidation/maintenance treatment (MY-PLAT)</measure>
    <time_frame>before autotransplant (MY-TAG), after 4 cycles (MY-DECT), every 6 months (MY-PLAT)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>partial response rate (&gt; or = 50%), PFS and OS since diagnosis, safety thalidomide + chemotherapy</measure>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <condition>Multiple Myeloma de Novo Treatment</condition>
  <arm_group>
    <arm_group_label>thalidomide + dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vincristin, Adriamycin, Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>thalidomide, melphalan, endoxan, dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>melphalan, endoxan, dexamethasone (MCDex)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide, Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>watch and wait</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide, Dexamethasone</intervention_name>
    <description>Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles</description>
    <arm_group_label>thalidomide + dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristin , Adriamycin, Dexamethasone = VAD</intervention_name>
    <description>Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle</description>
    <arm_group_label>Vincristin, Adriamycin, Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)</intervention_name>
    <description>Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles</description>
    <arm_group_label>thalidomide, melphalan, endoxan, dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan, endoxan, dexamethasone (MCDex)</intervention_name>
    <description>melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles</description>
    <arm_group_label>melphalan, endoxan, dexamethasone (MCDex)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide, Dexamethasone</intervention_name>
    <description>Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94</description>
    <arm_group_label>Thalidomide, Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  for MY-TAG(auto-transplant): age 18-65, multiple myeloma Salmon-Durie stage II, stage
             III and symptomatic stage I (lytic bone lesion or a 25 % increase of monoclonal
             protein)

          -  for MY-DECT (conventional chemotherapy) : qge 66-80, multiple myeloma Salmon-Durie
             stage II, stage III and symptomatic stage I (lytic bone lesion or a 25 % increase of
             monoclonal protein)

          -  for MY-PLAT (maintenance at plateau-phase): patients treated in MY-TAG or MY-DECt with
             at least a minimal response (25 % decrease of M protein)3-6 months after
             autotransplant or last chemotherapy

        Exclusion Criteria:

          -  for MY-TAG : age 66 or more, smoldering stage I multiple myeloma, previous therapy,
             plasma cell leukemia,creatinine &gt; 300 micromol/L, liver failure, anthracycline
             contra-indicated, thalidomide contra-indicated, corticosteroid contra-indicated

          -  for MY-DECT : age &lt; 66 or &gt; 80, smoldering stage I multiple myeloma, previous therapy,
             plasma cell leukemia,creatinine &gt; 300 micromol/L, liver failure, thalidomide
             contra-indicated, corticosteroid contra-indicated

          -  for MY-PLAT : no response or progressive disease, randomization &gt; 6 m since
             autotransplant or last chemotherapy, creatinine &gt; 300 micromol/L, liver failure,
             thalidomide contra-indicated, corticosteroid contra-indicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU CAEN Dept of Hematology</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Louis Dept of Hematology</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>February 17, 2010</last_update_submitted>
  <last_update_submitted_qc>February 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Margaret MACRO, MD</name_title>
    <organization>University hospital, Caen</organization>
  </responsible_party>
  <keyword>multiple myeloma, treatment, first line</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

